BHC Stock — Bausch Health Companies Inc

Bausch Health Companies Inc (BHC)

Updated October 16, 2026.

BHC is a Stock. Total return is 1777.2% over the past 32.6 years, 1123.0 points behind SPY at 2900.2%.

Bausch Health Companies Inc. is a diversified specialty pharmaceutical and medical device company operating through five segments: Salix (gastroenterology and hepatology), International, Solta Medical (aesthetic devices), Diversified (generic pharmaceuticals, dentistry, and over-the-counter products), and Bausch + Lomb (eye health). The company does not currently distribute to shareholders, though it has made special distributions in the past that should not be considered recurring income. This business appeals primarily to equity investors seeking exposure to the healthcare and pharmaceutical sector rather than income-focused investors.

BHC performance versus SPY

Price and return data through 2026-10-16.

Total return is 1777.2% over the past 32.6 years, 1123.0 points behind SPY at 2900.2%. Over the past year its total return — price change plus distributions reinvested — is 4.8%. Its deepest 1-year drawdown was 43.9%.

BHC key facts

Asset type

Stock

Asset class

Equity

Inception date

03/29/1994

Distribution frequency

None

5-year average yield

1.3

Last close

$6.30 (as of 2026-10-16)

Market cap

$2,356,140,534

Average volume

2164374.0

Ex-dividend date

11/10/2010

Payment date

12/22/2010

Beta

0.371

Payout ratio

0.0%

Forward P/E

1.3101

EPS

$-2.95

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

BHC risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 43.9%.

Who may consider BHC — and who may not

It is a weaker fit for investors who need monthly cash flow (BHC does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on BHC

• All tickers starting with B

Tagged: Healthcare.

Frequently asked questions